Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E56.55 EPS (ttm)6.41 Insider Own0.50% Shs Outstand107.53M Perf Week-1.22%
Market Cap38.95B Forward P/E25.16 EPS next Y14.40 Insider Trans-1.38% Shs Float77.50M Perf Month-11.73%
Income743.00M PEG3.04 EPS next Q2.71 Inst Own71.10% Short Float4.90% Perf Quarter-9.04%
Sales4.65B P/S8.38 EPS this Y85.10% Inst Trans0.69% Short Ratio5.31 Perf Half Y-10.92%
Book/sh38.96 P/B9.30 EPS next Y31.28% ROA13.00% Target Price466.48 Perf Year-32.50%
Cash/sh9.72 P/C37.27 EPS next 5Y18.62% ROE20.10% 52W Range329.09 - 592.59 Perf YTD-33.27%
Dividend- P/FCF37.01 EPS past 5Y44.90% ROI16.00% 52W High-38.87% Beta1.76
Dividend %- Quick Ratio3.10 Sales past 5Y55.00% Gross Margin91.40% 52W Low10.08% ATR9.40
Employees4300 Current Ratio3.40 Sales Q/Q21.40% Oper. Margin26.70% RSI (14)32.52 Volatility2.03% 2.59%
OptionableYes Debt/Eq0.09 EPS Q/Q0.00% Profit Margin16.00% Rel Volume0.71 Prev Close363.53
ShortableYes LT Debt/Eq0.09 EarningsNov 04 BMO Payout0.00% Avg Volume715.50K Price362.25
Recom2.40 SMA20-6.72% SMA50-8.92% SMA200-8.43% Volume509,812 Change-0.35%
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-25-16Downgrade Chardan Capital Markets Neutral → Sell $525 → $400
Jan-20-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Wells Fargo Outperform
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Oct-24-16 05:35PM  Know This Sell Signal: When Stock Leaders Stage Big Downside Reversals
Oct-21-16 09:30AM  Regeneron Announces Presentation at the 25th Annual Credit Suisse Healthcare Conference PR Newswire
08:00AM  Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry
Oct-20-16 08:06AM  What Are the Drivers behind the Success of Soliris?
Oct-19-16 06:04PM  Will Alexion Beat Investor Expectations in Its 3Q16 Earnings?
03:55PM  How Much Return Could Alexion Offer over the Next 12 months?
10:11AM  Biotech Stock Roundup: ARIAD Down on Drug Pricing Tweet, Regeneron Study on Clinical Hold
Oct-18-16 11:40AM  FDA Holds Regeneron, Teva Pain Study (REGN, TEVA) at Investopedia
11:12AM  Weighing Vertex Pharmaceuticals Attributes before It Reports
09:25AM  Regeneron & Teva Hit by Clinical Hold on Chronic Pain Study
Oct-17-16 11:57AM  FDA Puts Hold on Regeneron Pain-Drug Study at TheStreet
08:09AM  News Of Clinical Hold For Fasinumab Weighs On Regeneron, Teva Shares
07:27AM  FDA places Regeneron and Teva's pain-drug study on hold Reuters
07:23AM  Regeneron stock slumps nearly 2% after FDA puts hold on midstage clinical trial at MarketWatch
07:00AM  Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs PR Newswire
Oct-14-16 10:27AM  Ocular's (OCUL) Stock Jumps on Collaboration with Regeneron
09:11AM  Blog Coverage Ocular Therapeutix Announces a Potential 315 Million Dollar Drug Development Deal with Regeneron Pharma
Oct-13-16 09:27PM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche Holding AG at Motley Fool
04:13PM  Regeneron, Ocular to Develop Eye Drug (REGN, OCUL) at Investopedia
12:51PM  Regeneron: Today is the Greatest Day I've Ever Known at
12:05PM  Ocular Therapeutix (OCUL) Stock Soars on Regeneron Deal
11:16AM  Heres Why Amazon, Alphabet, Ocular Therapeutix, and Two Other Stocks Are Trending on Thursday at Insider Monkey
10:48AM  Bedford's Ocular Therapeutix inks potential $315M deal with Regeneron at
09:22AM  Ocular Therapeutix stock up 26% on $10 mln Regeneron drug development deal at MarketWatch
09:05AM  Why Ocular Therapeutix Is Winning Big With Its Regeneron Collaboration at 24/7 Wall St.
Oct-11-16 07:01PM  Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide at TheStreet
03:06PM  Pitney Bowes relocating to new offices next year at
08:21AM  Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.? at Motley Fool
Oct-09-16 12:13PM  The Big Reason You Shouldn't Give Up on Big-Cap Biotech at Motley Fool
Oct-08-16 08:16AM  Here's Why Ophtotech Corporation Dropped 16.5% in September at Motley Fool
Oct-07-16 11:51AM  Will Biogen Join Gilead in the Disappointment Club? at
09:30AM  Regeneron to Report Third Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2016 PR Newswire
Oct-06-16 04:44PM  Ophthotech's Eye Disease Med Could Beat Down Rival Regeneron
Oct-05-16 03:56PM  In Your 40s? 3 Stocks You Should Consider Buying at Motley Fool
02:26PM  Two Biotech Companies That Have Taken A Hit In The Past Week at Insider Monkey
09:29AM  Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data
08:30AM  New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease PR Newswire
Oct-04-16 08:42AM  5 FDA Decisions to Watch Out for in October 2016
Oct-03-16 12:35PM  Regeneron Drug Fails in Combination Trial (REGN) at Investopedia
11:57AM  Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista
10:40AM  Regeneron's Eylea/Rinucumab Combination Data Disappoints
Oct-01-16 02:00AM  Regeneron eczema drug reduces itch and anxiety, two studies show Reuters
02:00AM  Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine PR Newswire
Sep-30-16 07:00PM  Why Cognizant Technology Solutions, Pier 1 Imports, and Ophthotech Slumped Today at Motley Fool
04:55PM  [$$] Regeneron Bulls Should Keep Eye on the Prize at
04:48PM  Regeneron Pharmaceuticals Falls As Combo Therapy Worse Than Eylea Alone
04:44PM  Why Investors Are Paying a Premium for Regeneron Pharmaceuticals, Inc. at Motley Fool
04:20PM  What Will Gilead Try Buying Next? Polls Offer Some 'Incyte'
02:37PM  Chardan Rates Regeneron A Sell, Advises Caution
12:29PM  Here's Why Ophthotech Corporation Is Dropping Today at Motley Fool
10:05AM  What Do Analysts Say about Regenerons Upside Potential?
09:47AM  Why RBS, Cheniere Energy, Regeneron Pharmaceuticals & Two Other Stocks Are in Spotlight Today at Insider Monkey
08:05AM  Regeneron Is a Late Entrant in Immuno-Oncology Space
07:43AM  Regeneron's Eylea combination therapy fails mid-stage study Reuters
07:00AM  Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration PR Newswire
Sep-29-16 04:26PM  Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure
02:04PM  Why Teva and Regeneron Entered Collaboration Agreement
12:04PM  How Regeneron Is Working to Maintain Eyleas Dominance
10:33AM  How Does Regenerons 2016 Guidance Look?
Sep-28-16 10:04AM  Whats the Word on Street for Vertex?
Sep-27-16 04:05PM  BioMarin to Cross $1 Billion Revenue in 2016
01:30PM  Goldman Sachs: Pharma Stocks That Need Price Hikes to Thrive Better Find a New Strategy Fast at
11:23AM  The Drug Price Increase Debate: Separating The Winners From The Losers
09:30AM featured highlights: Regeneron Pharmaceuticals, Nordstrom, Intel, Nu Skin Enterprises and Priceline featured highlights: Regeneron Pharmaceuticals, Nordstrom, Intel, Nu Skin Enterprises and Priceline Group
08:34AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : September 27, 2016
Sep-26-16 04:32PM  Regeneron-Sanofi Could Beat Pfizer, Roche, AstraZeneca On Eczema
03:55PM  Regeneron, Sanofi Skin Disease Drug Under Priority Review
02:22PM  Regeneron Win Review for Dermatitis Drug (REGN) at Investopedia
07:15AM  FDA set to decide on two likely blockbuster drugs by Sanofi Genzyme at
03:24AM  Sanofi may win U.S. approval of $3 bln eczema drug by March Reuters
01:01AM  Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA GlobeNewswire
01:00AM  Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA PR Newswire
Sep-22-16 11:17AM  [$$] Teva, Allergan Pump Up the Pipelines at
Sep-21-16 03:08PM  Regeneron, Teva Collaborate to Develop Chronic Pain Drug
11:05AM  Ioniss Orphan Drug in Third Phase of Clinical Trials
08:39AM  Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
12:30AM  Regeneron to Collaborate With Teva for Fasinumab Drug (REGN, TEVA) at Investopedia
Sep-20-16 07:01AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
07:00AM  Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain Business Wire
07:00AM  Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain PR Newswire
Sep-19-16 08:25AM  RBC Says These 4 Top Biotechs Could Have Big Upside Potential at 24/7 Wall St.
Sep-18-16 02:57PM  5 Trade Ideas for Monday: TD Ameritrade, AstraZeneca, Costco, International Paper and Regeneron
Sep-16-16 12:49PM  Vertex: Did Management Deliver Investors a Backhanded Slap? at
Sep-14-16 04:28PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Sep-13-16 11:52AM  Regeneron Pharmaceuticals, Inc. Value Analysis (NASDAQ:REGN) : September 13, 2016
Sep-12-16 08:30AM  Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors PR Newswire
08:13AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : September 12, 2016
Sep-06-16 08:15AM  A $14,000 Price Tag For A Cholesterol Drug Can Be A Bargain at Forbes
Sep-03-16 02:50PM  3 Biotech Stocks to Buy in September at Motley Fool
09:35AM  3 Large-Cap Stocks to Buy in September at Motley Fool
Sep-01-16 03:51PM  3 Stocks That Turned $3,000 Into $30,000 or More! at Motley Fool
10:04AM  Regenerons Growth Opportunities: Praluent, Sarilumab, and Dupilumab
09:30AM  Regeneron Announces Upcoming 2016 Investor Conference Presentations PR Newswire
08:07AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : September 1, 2016
08:04AM  Restricted Access Continues to Impact Praluent Sales in 2016
Aug-31-16 06:09PM  3 Beaten-Up Biotech Stocks: Are They Bargains? at Motley Fool
11:53AM  Why Eylea Could Face Tough Competition in 2016
11:53AM  What Are Analysts Recommendations for Regeneron in 2016?
11:53AM  Regenerons Valuation Multiples Compared to Its Peers
10:24AM  Biotech: In Unfamiliar Territory? at
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products; and collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize fasinumab, an investigational NGF antibody in Phase III clinical development for osteoarthritis pain and in Phase II development for chronic low back pain. The company also has a strategic collaboration, option, and license agreement with Ocular Therapeutix for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other retinal diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Option Exercise52.033,954205,72710,820Dec 29 07:44 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Sale552.083,9542,182,9246,866Dec 29 07:44 PM
Aberman Michael SSVP Strategy Investor RelationDec 17Option Exercise24.004,00096,00016,498Dec 18 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise52.031,92199,95017,742Dec 18 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise52.031,92199,9506,866Dec 18 04:28 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise52.031,92199,950501,921Dec 18 04:26 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 16Option Exercise52.031,92199,9501,921Dec 18 04:27 PM
STAHL NEILEVP Research and DevelopmentDec 16Option Exercise52.031,92199,95027,594Dec 18 04:27 PM
BROWN MICHAEL SDirectorDec 10Option Exercise177.823,000533,4603,000Dec 11 04:14 PM
BROWN MICHAEL SDirectorDec 10Sale546.453,0001,639,3650Dec 11 04:14 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 02Sale549.0343,34823,799,539500,000Dec 04 04:13 PM
SING GEORGE LDirectorNov 18Option Exercise19.693,00059,070115,772Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.00500290,0004,500Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.003,0001,740,000112,772Nov 20 04:04 PM
VAGELOS P ROYChairman of the BoardNov 18Sale587.9017,24010,135,312334,611Nov 19 04:20 PM
STAHL NEILEVP Research and DevelopmentNov 09Sale560.0522,10112,377,55922,029Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 06Sale563.0020,00011,260,06844,130Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 05Option Exercise28.29100,0002,828,50097,029Nov 09 05:10 PM
VAGELOS P ROYChairman of the BoardNov 03Sale580.233,9852,312,217351,851Nov 04 04:05 PM
VAGELOS P ROYChairman of the BoardNov 02Sale580.1813,2577,691,446355,836Nov 04 04:05 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriNov 02Sale571.6143,34824,778,125543,348Nov 03 04:20 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriOct 30Option Exercise11.64182,8182,128,002682,818Nov 03 04:20 PM